Crinetics Pharmaceuticals (CRNX) Accumulated Expenses (2017 - 2026)

Crinetics Pharmaceuticals has reported Accumulated Expenses for 10 years, with the latest figure at $25.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 55.32% year-over-year to $25.8 million; the trailing twelve-month figure through Mar 2026 stood at $25.8 million (up 55.32% YoY), and the FY2025 full-year result was $35.6 million, up 23.16% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $25.8 million, down from $35.6 million in the prior quarter.
• The five-year high for Accumulated Expenses was $35.6 million in Q4 2025, with the low at $4.5 million in Q1 2022.
• Average Accumulated Expenses over 5 years is $17.2 million, with a median of $14.8 million recorded in 2024.
• Year-over-year, Accumulated Expenses jumped 137.03% in 2024 and climbed 6.97% in 2025.
• Tracing CRNX's Accumulated Expenses over 5 years: stood at $9.1 million in 2022, then surged by 59.86% to $14.5 million in 2023, then surged by 98.99% to $28.9 million in 2024, then gained by 23.16% to $35.6 million in 2025, then slipped by 27.51% to $25.8 million in 2026.
• The last three Accumulated Expenses figures came in at $25.8 million (Q1 2026), $35.6 million (Q4 2025), and $32.4 million (Q3 2025), per Business Quant data.

Peer Comparison